Evotec (OTCMKTS: EVTCY) is one of 526 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Evotec to similar businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.
This is a summary of recent recommendations for Evotec and its competitors, as provided by MarketBeat.com.
||Strong Buy Ratings
As a group, “Pharmaceutical preparations” companies have a potential upside of 58.03%. Given Evotec’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Evotec has less favorable growth aspects than its competitors.
This table compares Evotec and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Evotec and its competitors gross revenue, earnings per share (EPS) and valuation.
Evotec’s competitors have higher revenue and earnings than Evotec. Evotec is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
46.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.3% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
Evotec has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Evotec’s competitors have a beta of 0.94, suggesting that their average share price is 6% less volatile than the S&P 500.
Evotec competitors beat Evotec on 9 of the 13 factors compared.
Evotec Company Profile
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a strategic drug discovery and development partnership with Celgene Corporation to identify therapeutics in oncology; a strategic alliance with Novo Nordisk A/S to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities; collaboration with Sanofi to develop LAB031, which accelerates drug discovery across various therapeutic areas; a strategic research collaboration with Almirall, S.A. to discover and develop first-in-class therapeutics in the field of dermatology diseases; and a strategic research alliance with Ferring Pharmaceuticals to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions, as well as a strategic collaboration agreement with Centogene AG. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.